publication . Article . 2016

Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells

Pallis, Monica; Burrows, Francis; Ryan, Jeremy; Grundy, Martin; Seedhouse, Claire; Abdul-Aziz, Amina; Montero, Joan; Letai, Anthony; Russell, Nigel;
  • Published: 15 Apr 2016
// Monica Pallis 1 , Francis Burrows 2 , Jeremy Ryan 3 , Martin Grundy 1 , Claire Seedhouse 4 , Amina Abdul-Aziz 4 , Joan Montero 3 , Anthony Letai 3 , Nigel Russell 1, 4 1 Clinical Haematology, Nottingham University Hospitals, Nottingham, UK 2 Tragara Pharmaceuticals, Carlsbad, CA, USA 3 Department of Medical Oncology, Harvard Medical School, Boston, MA, USA 4 Department of Haematology, University of Nottingham, Nottingham, UK Correspondence to: Monica Pallis, e-mail: Keywords: BAD, NOXA, TG02, ABT-199, AML Received: January 04, 2016      Accepted: March 28, 2016      Published: April 15, 2016 ABSTRACT Direct co-operation between ...
free text keywords: AML, TG02, hemic and lymphatic diseases, BAD, biological phenomena, cell phenomena, and immunity, ABT-199, NOXA, Research Paper, Oncology, Kinase, Antagonist, Cytochrome c, biology.protein, biology, Hematology, medicine.medical_specialty, medicine, Drug action, Immunology, Apoptosis, Myeloid Cell Leukemia Sequence 1 Protein, Cytotoxic T cell, Cancer research, business.industry, business, Internal medicine, BAD, NOXA, TG02, ABT-199, AML
40 references, page 1 of 3

Czabotar, PE, Lessene, G, Strasser, A, Adams, JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nature reviews Molecular cell biology. 2014; 15: 49-63 [OpenAIRE] [PubMed] [DOI]

Davids, MS, Letai, A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012; 30: 3127-3135 [OpenAIRE] [PubMed] [DOI]

Brunelle, JK, Ryan, J, Yecies, D, Opferman, JT, Letai, A. MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. The Journal of cell biology. 2009; 187: 429-442 [OpenAIRE] [PubMed] [DOI]

Vo, TT, Ryan, J, Carrasco, R, Neuberg, D, Rossi, DJ, Stone, RM, Deangelo, DJ, Frattini, MG, Letai, A. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012; 151: 344-355 [OpenAIRE] [PubMed] [DOI]

Manome, Y, Weichselbaum, RR, Kufe, DW, Fine, HA. Effect of Bcl-2 on ionizing radiation and 1-beta-D-arabinofuranosylcytosine-induced internucleosomal DNA fragmentation and cell survival in human myeloid leukemia cells. Oncology research. 1993; 5: 139-144 [PubMed]

Keith, FJ, Bradbury, DA, Zhu, Y-M, Russell, NH. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia. 1995; 9: 131-138 [PubMed]

Zhou, P, Qian, L, Kozopas, KM, Craig, RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood. 1997; 89: 630-643 [PubMed]

Dai, Y, Grant, S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res. 2007; 67: 2908-2911 [PubMed] [DOI]

Chen, S, Dai, Y, Harada, H, Dent, P, Grant, S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 2007; 67: 782-791 [OpenAIRE] [PubMed] [DOI]

Chen, L, Willis, SN, Wei, A, Smith, BJ, Fletcher, JI, Hinds, MG, Colman, PM, Day, CL, Adams, JM, Huang, DC. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecular cell. 2005; 17: 393-403 [OpenAIRE] [PubMed] [DOI]

Konopleva, M, Contractor, R, Tsao, T, Samudio, I, Ruvolo, PP, Kitada, S, Deng, X, Zhai, D, Shi, YX, Sneed, T, Verhaegen, M, Soengas, M, Ruvolo, VR, McQueen, T, Schober, WD, Watt, JC. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006; 10: 375-388 [OpenAIRE] [PubMed] [DOI]

Konopleva, M, Milella, M, Ruvolo, P, Watts, JC, Ricciardi, MR, Korchin, B, McQueen, T, Bornmann, W, Tsao, T, Bergamo, P, Mak, DH, Chen, W, McCubrey, J, Tafuri, A, Andreeff, M. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia. 2012; 26: 778-787 [OpenAIRE] [PubMed] [DOI]

Chen, S, Dai, Y, Pei, XY, Myers, J, Wang, L, Kramer, LB, Garnett, M, Schwartz, DM, Su, F, Simmons, GL, Richey, JD, Larsen, DG, Dent, P, Orlowski, RZ, Grant, S. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res. 2012; 72: 4225-4237 [OpenAIRE] [PubMed] [DOI]

Souers, AJ, Leverson, JD, Boghaert, ER, Ackler, SL, Catron, ND, Chen, J, Dayton, BD, Ding, H, Enschede, SH, Fairbrother, WJ, Huang, DC, Hymowitz, SG, Jin, S, Khaw, SL, Kovar, PJ, Lam, LT. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19: 202-208 [OpenAIRE] [PubMed] [DOI]

Gibson, CJ, Davids, MS. BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis. Clinical cancer research. 2015; 21: 5021-5029 [OpenAIRE] [PubMed] [DOI]

40 references, page 1 of 3
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue